Brief: Knight Therapeutics Enters Into Exclusive Supply And Distribution Agreement With Incyte
23/09/2021 12:33
Sept 23 (Reuters) - Knight Therapeutics Inc GUD.TO :
* KNIGHT THERAPEUTICS ENTERS INTO EXCLUSIVE SUPPLY AND
DISTRIBUTION AGREEMENT WITH INCYTE FOR TAFASITAMAB AND
PEMIGATINIB IN LATIN AMERICA
* KNIGHT THERAPEUTICS INC - INCYTE WILL BE RESPONSIBLE FOR
DEVELOPMENT, MANUFACTURE AND SUPPLY TO KNIGHT OF TAFASITAMAB AND
PEMIGATINI
* KNIGHT THERAPEUTICS - WILL BE RESPONSIBLE FOR SEEKING
NECESSARY
REGULATORY APPROVALS AND DISTRIBUTING BOTH MEDICINES IN LATIN
AMERICA
Source text for Eikon: ID:nGNX63mdkr
Further company coverage: GUD.TO
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil